The $17 Blood Test That Could Rewrite Alzheimer's Diagnosis
ALZpath just handed Abbott the keys to a blood test that spots Alzheimer's almost as well as a $5,000 brain scan. The science is ready; now it's a race against reimbursement.
Right now, catching Alzheimer's disease early usually means one of two things: a $5,000+ PET scan of your brain, or a needle in your spine to collect cerebrospinal fluid. Both are expensive, invasive, and about as fun as they sound. Which means millions of people who could benefit from early detection simply don't get tested.
A deal announced this week could change that math entirely.
A Blood Draw Instead of a Brain Scan
ALZpath, a company that's built one of the most validated blood biomarkers for Alzheimer's, just signed a global licensing agreement with Abbott Laboratories. The arrangement gives Abbott the rights to use ALZpath's proprietary antibody to build an Alzheimer's blood test on its Alinity ci-series lab analyzers, one of the largest installed bases of diagnostic equipment on the planet.
Think of it like this: ALZpath built the recipe, and Abbott owns the restaurant chain. Now they're putting that dish on menus worldwide.
The deal is royalty-based, meaning ALZpath gets paid as tests get used rather than collecting a one-time check. Specific financial terms (upfront payments, milestones, royalty rates) weren't disclosed. But the strategic implications are loud and clear.
Why This Biomarker Matters
The antibody at the center of this deal targets something called p-tau217 (phosphorylated tau at position 217), a protein fragment that shows up in the blood when Alzheimer's pathology is building in the brain. It's like smoke before the fire: detectable years, potentially up to 15 years, before symptoms appear.
And the accuracy numbers are striking. Across multiple independent studies and over 200 peer-reviewed publications in 18 countries, ALZpath's p-tau217 test has shown AUCs (a measure of diagnostic accuracy where 1.0 is perfect) ranging from 0.92 to 0.97 against both amyloid and tau PET scans. For context, that's comparable to the gold-standard spinal fluid tests. In one clinical lab evaluation, a two-cutoff approach delivered sensitivity of nearly 95% and , depending on which threshold was applied.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
specificity above 95%
In plain English: the blood test is almost as good as the brain scan at spotting Alzheimer's biology. And it requires nothing more than a standard blood draw.
Abbott's 80% Play
ALZpath CEO Mike Banville dropped a number that puts this deal in perspective. With Abbott now on board, ALZpath's p-tau217 antibody will be used by partners covering approximately 80% of the in vitro diagnostic market. That's not a niche play; it's a near-monopoly on the underlying technology.
ALZpath has been running a multi-partner licensing strategy, supplying its antibody to various diagnostic companies rather than going exclusive with one. Abbott is the biggest name yet, joining an ecosystem that already includes Roche, Beckman Coulter, Siemens Healthineers, Quanterix, Bio-Techne, Alamar Biosciences, and others. Each partner builds its own test on its own platform, but ALZpath's antibody sits inside all of them.
It's a bit like Qualcomm selling chips to every smartphone maker. You might not see ALZpath's name on the test, but their technology is doing the work.
A Crowded Race With Real Stakes
ALZpath and Abbott aren't operating in a vacuum. The blood-based Alzheimer's diagnostics space has gotten intensely competitive over the past year.
Fujirebio earned the first FDA-cleared Alzheimer's blood test in May 2025, using a p-tau217/amyloid ratio on its Lumipulse platform. Roche followed with an FDA-cleared p-tau181 blood test in October 2025, specifically targeting primary care settings. Quanterix provides ultra-sensitive detection platforms used across research and clinical labs, while C2N Diagnostics offers mass-spectrometry-based approaches.
The competitive dynamics are shifting fast, especially as p-tau217 increasingly looks like the superior biomarker.
What Abbott brings to this race is sheer scale. Those Alinity analyzers already sit in hospitals and reference labs around the world. When Abbott's test gets regulatory clearance, it won't need a new install; it'll slot into machines that are already running thousands of other tests daily.
The Reimbursement Problem Nobody Wants to Talk About
There's a catch, and it's a big one.
After Fujirebio's blood test got FDA clearance, CMS (the agency that runs Medicare) initially proposed paying labs just $17 per test. An advisory panel recommended $130. That gap tells you everything about where the tension lies: the science is ready, but the economics are still being negotiated.
The broader Alzheimer's diagnostics market is projected to hit roughly $9 to $10 billion globally in 2025, growing at around 11% annually. Blood tests are the fastest-growing segment, expanding at mid-teens to 20%+ CAGR. But reimbursement friction remains the single biggest bottleneck to widespread adoption.
Without adequate payment, labs have little incentive to offer the tests. And without clear Medicare coverage pathways (the ASAP Act was still pending in Congress as of mid-2026), the promise of accessible blood-based screening stays theoretical for many patients.
What This Actually Changes for Patients
So who benefits, and when?
In the near term, expect p-tau217 blood tests to show up first in memory clinics and neurology practices, used as a triage tool. Got a positive blood test? You might still get a PET scan to confirm. Got a negative one? You can probably skip the $5,000 imaging and the spinal tap.
The bigger shift comes as disease-modifying Alzheimer's drugs (like the anti-amyloid antibodies already on the market) expand their reach. Those treatments require confirmed Alzheimer's pathology before starting. A scalable blood test turns what was a diagnostic bottleneck into a routine lab order.
Over three to five years, if reimbursement catches up and guidelines evolve, p-tau217 testing could move into primary care. Your family doctor could order it alongside your cholesterol panel. That's the vision, anyway.
The Bottom Line
The ALZpath-Abbott deal isn't just another licensing agreement. It's a bet that Alzheimer's diagnosis is about to undergo the same transformation that troponin tests brought to heart attacks: from expensive, specialized procedures to routine blood work.
The science is there. The platform is there. The global infrastructure is there. Now the question is whether regulators and payers will move fast enough to let patients actually benefit. Because having the best blood test in the world doesn't matter much if nobody can afford to run it.
Clinical & Regulatory
4 min read
Trodelvy Just Jumped the Line in Breast Cancer Treatment
The FDA just moved Gilead's Trodelvy from last-resort to first-choice in triple-negative breast cancer, the deadliest breast cancer subtype. It's a seismic shift for patients, a multi-billion-dollar opportunity for Gilead, and a surprisingly friendly outcome for Merck's Keytruda.
